Charles Schwab’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $61.1M | Buy |
193,238
+10,351
| +6% | +$2.44M | 0.01% | 1104 |
|
|
2026
Q1 | $36.5M | Sell |
182,887
-1,397
| -0.8% | -$276K | 0.01% | 1372 |
|
|
2025
Q4 | $34.8M | Buy |
184,284
+1,969
| +1% | +$378K | 0.01% | 1393 |
|
|
2025
Q3 | $32.3M | Buy |
182,315
+6,251
| +4% | +$929K | 0.01% | 1439 |
|
|
2025
Q2 | $20M | Buy |
176,064
+7,190
| +4% | +$768K | ﹤0.01% | 1675 |
|
|
2025
Q1 | $17.8M | Sell |
168,874
-1,545
| -0.9% | -$175K | ﹤0.01% | 1696 |
|
|
2024
Q4 | $18.3M | Buy |
170,419
+6,495
| +4% | +$734K | ﹤0.01% | 1745 |
|
|
2024
Q3 | $16.4M | Buy |
163,924
+8,584
| +6% | +$864K | ﹤0.01% | 1804 |
|
|
2024
Q2 | $13.1M | Buy |
155,340
+5,564
| +4% | +$443K | ﹤0.01% | 1905 |
|
|
2024
Q1 | $10.9M | Sell |
149,776
-11,704
| -7% | -$863K | ﹤0.01% | 1941 |
|
|
2023
Q4 | $11.5M | Buy |
161,480
+4,293
| +3% | +$253K | ﹤0.01% | 1910 |
|
|
2023
Q3 | $9.42M | Buy |
157,187
+2,761
| +2% | +$182K | ﹤0.01% | 1938 |
|
|
2023
Q2 | $11.1M | Buy |
154,426
+7,293
| +5% | +$547K | ﹤0.01% | 1867 |
|
|
2023
Q1 | $10.8M | Sell |
147,133
-21,493
| -13% | -$1.53M | ﹤0.01% | 1836 |
|
|
2022
Q4 | $11.3M | Sell |
168,626
-88,779
| -34% | -$5.77M | ﹤0.01% | 1797 |
|
|
2022
Q3 | $13.8M | Buy |
257,405
+2,425
| +1% | +$143K | 0.01% | 1641 |
|
|
2022
Q2 | $14.2M | Buy |
254,980
+7,347
| +3% | +$417K | ﹤0.01% | 1630 |
|
|
2022
Q1 | $17.4M | Buy |
247,633
+2,033
| +0.8% | +$148K | 0.01% | 1654 |
|
|
2021
Q4 | $23.7M | Buy |
245,600
+15,156
| +7% | +$1.4M | 0.01% | 1450 |
|
|
2021
Q3 | $20M | Buy |
230,444
+10,556
| +5% | +$816K | 0.01% | 1584 |
|
|
2021
Q2 | $18M | Buy |
219,888
+12,258
| +6% | +$1.02M | 0.01% | 1658 |
|
|
2021
Q1 | $19.7M | Buy |
207,630
+13,499
| +7% | +$1.28M | 0.01% | 1542 |
|
|
2020
Q4 | $12M | Buy |
194,131
+1,271
| +0.7% | +$72.5K | ﹤0.01% | 1751 |
|
|
2020
Q3 | $11.5M | Buy |
192,860
+27,597
| +17% | +$1.88M | 0.01% | 1594 |
|
|
2020
Q2 | $11.5M | Sell |
165,263
-1,579
| -0.9% | -$100K | 0.01% | 1558 |
|
|
2020
Q1 | $7.57M | Sell |
166,842
-9,417
| -5% | -$534K | ﹤0.01% | 1618 |
|
|
2019
Q4 | $11.5M | Sell |
176,259
-48,870
| -22% | -$3.27M | 0.01% | 1598 |
|
|
2019
Q3 | $14M | Sell |
225,129
-62,055
| -22% | -$3.9M | 0.01% | 1384 |
|
|
2019
Q2 | $20.5M | Sell |
287,184
-33,722
| -11% | -$2.48M | 0.01% | 1119 |
|
|
2019
Q1 | $25.2M | Buy |
320,906
+27,554
| +9% | +$2.09M | 0.02% | 968 |
|
|
2018
Q4 | $24.8M | Buy |
293,352
+16,318
| +6% | +$1.74M | 0.02% | 845 |
|
|
2018
Q3 | $47.4M | Buy |
277,034
+59,233
| +27% | +$8.93M | 0.03% | 557 |
|
|
2018
Q2 | $28.1M | Buy |
217,801
+2,497
| +1% | +$279K | 0.02% | 830 |
|
|
2018
Q1 | $22.2M | Buy |
215,304
+5,725
| +3% | +$566K | 0.02% | 927 |
|
|
2017
Q4 | $17.9M | Buy |
209,579
+4,728
| +2% | +$410K | 0.01% | 1067 |
|
|
2017
Q3 | $17.4M | Buy |
204,851
+27,365
| +15% | +$2.17M | 0.02% | 1033 |
|
|
2017
Q2 | $13.4M | Buy |
177,486
+12,443
| +8% | +$870K | 0.01% | 1130 |
|
|
2017
Q1 | $10.9M | Buy |
165,043
+27,089
| +20% | +$1.78M | 0.01% | 1260 |
|
|
2016
Q4 | $8.74M | Buy |
137,954
+6,264
| +5% | +$395K | 0.01% | 1357 |
|
|
2016
Q3 | $8.38M | Buy |
131,690
+5,268
| +4% | +$387K | 0.01% | 1292 |
|
|
2016
Q2 | $9.41M | Buy |
126,422
+1,319
| +1% | +$97.9K | 0.01% | 1112 |
|
|
2016
Q1 | $8.36M | Sell |
125,103
-48,664
| -28% | -$2.96M | 0.01% | 1155 |
|
|
2015
Q4 | $11.8M | Sell |
173,767
-20,637
| -11% | -$1.27M | 0.02% | 910 |
|
|
2015
Q3 | $10.4M | Buy |
194,404
+5,731
| +3% | +$348K | 0.02% | 960 |
|
|
2015
Q2 | $11.9M | Sell |
188,673
-186,400
| -50% | -$10.2M | 0.02% | 898 |
|
|
2015
Q1 | $18M | Buy |
375,073
+22,708
| +6% | +$870K | 0.03% | 607 |
|
|
2014
Q4 | $11.7M | Buy |
352,365
+105,885
| +43% | +$3.44M | 0.02% | 784 |
|
|
2014
Q3 | $7.23M | Buy |
246,480
+103,617
| +73% | +$3.44M | 0.01% | 1064 |
|
|
2014
Q2 | $5.55M | Buy |
142,863
+58,173
| +69% | +$2.36M | 0.01% | 1312 |
|
|
2014
Q1 | $3.55M | Buy |
84,690
+3,896
| +5% | +$162K | 0.01% | 1596 |
|
|
2013
Q4 | $2.65M | Buy |
80,794
+3,190
| +4% | +$104K | 0.01% | 1727 |
|
|
2013
Q3 | $2.2M | Buy |
77,604
+2,683
| +4% | +$75.5K | ﹤0.01% | 1786 |
|
|
2013
Q2 | $1.86M | Buy |
+74,921
| New | +$1.35M | ﹤0.01% | 1803 |
|
Other funds holding LGND
JT
CAM
Charles Schwab's LGND Position: Q2 2026 in Review
Charles Schwab increased its Ligand Pharmaceuticals (LGND) stake by 5.7% in Q2 2026, buying an estimated $2.44M and bringing the position to 193,238 shares worth $61.1M. The position accounts for 0.01% of the portfolio, ranked #1104.
Charles Schwab first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Charles Schwab held 193,238 shares of Ligand Pharmaceuticals worth $61.1M as of Q2 2026.
- Charles Schwab bought 10,351 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.44M.
- Ligand Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1104 holding.
- Charles Schwab first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.